A Randomized, Double-blind, Placebo-controlled, Study to Identify the Opioid-sparing Effects, and Pain-reduction Potential of Low Dose Ketamine on Patients Undergoing TEVAR Procedures Receiving NCI
| Registry | NCT04600089, acronym 2020Ketamine |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional; randomized, parallel, masking: quadruple, treatment |
| Enrollment | 21 (Actual) |
| Sponsor | Eric Johnson (Other) |
| Conditions | Descending Aortic Dissection, Postoperative Pain, Thoracoabdominal Aortic Aneurysm |
| Interventions | Saline, Ketamine (Drug) |
| Dates | start 2020-12-08, primary completion 2025-10-17, completion 2025-10-17, first posted 2020-10-23, last updated 2026-09-21 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
All trials for Descending Aortic Dissection All trials for Postoperative Pain All trials of Saline All trials of Ketamine
The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).
Patients undergoing descending aortic repair often experience post-operative pain, and have high post operative opioid requirements. That pain is partially due to the use of naloxone continuous infusion (NCI). NCI is part of a bundled approach used in the first 48 hours post-operatively to prevent spinal cord ischemia, a devastating complication associated with surgical repair of the descending aortic. Data indicate that patients receiving NCI experience elevated post-operative pain scores and increased opioid requirements during the 48-hr post-operative NCI administration, compared to patients not receiving NCI.
Ketamine is an FDA-approved N-methyl D-aspartate (NMDA) antagonist that has been shown to provide adjunctive analgesia and opioid-sparing effects in post-operative surgical patients. At low doses, ketamine provides analgesic benefit without the anesthetic effects seen at higher doses. These doses are commonly referred to sub-dissociative. This study will evaluate whether use of sub dissociative ketamine (SDK) in patients undergoing aortic procedures with the use of NCI will lead to decreased post-operative opioid consumption, and produce improved pain scores in the first 48 hours.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Standard of Care | Placebo comparator | Drug: Saline | Participants in this group will receive standard of care as well as a saline infusion during the study period. |
| Sub-Dissociative Ketamine | Experimental | Drug: Ketamine | Participants in this group will receive standard of care as well as a continuous ketamine infusion at the induction of anesthesia and for 48 hours postoperatively. |
Sex: All, ages: 18 Years to 90 Years
Inclusion Criteria: * willing to give informed consent * scheduled for elective thoracic aorta repair or thoracoabdominal aortic repair * requires naloxone continuous infusion for spinal prophylaxis Exclusion Criteria: * allergy to ketamine, acetaminophen, or fentanyl * diagnosis of schizophrenia * history of hydrocephalus or central nervous system mass * incarcerated individuals * pregnant or lactating individuals
| Facility | City | Country | Status |
|---|---|---|---|
| University of Kentucky Medical Center | Lexington, Kentucky | United States |